6月27日信达生物研发的首款国产减重创新药玛仕度肽注射液(商品名:信尔美)获国家药监局批准上市用于成人肥胖或超重患者的长

智通财经
27 Jun
6月27日信达生物研发的首款国产减重创新药玛仕度肽注射液(商品名:信尔美)获国家药监局批准上市用于成人肥胖或超重患者的长期体重控制。该药物也是全球首个GCG/GLP-1双受体激动减重药物有望打破目前由跨国巨头诺和诺德、礼来主导的全球减重药领域双雄争霸的格局。 该药品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制初始体重指数(BMI)为:BMI≥28 kg/㎡(肥胖);或BMI≥24 kg/㎡(超重)并伴有至少一种体重相关的合并症(例如高血糖、高血压、血脂异常、脂肪肝、阻塞性睡眠呼吸暂停综合征等)。(第一财经)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10